back to release list
Immunovaccine to Present Data on Cancer Vaccine Combination Therapies at the 2014 AACR Annual Meeting
Combining with cyclophosphamide and the checkpoint inhibitor anti-PD-1 enhances the therapeutic potential of vaccine
Halifax, Nova Scotia; April 3, 2014 – Immunovaccine Inc. (“Immunovaccine” or “IMV”) (TSX-V: IMV), a clinical stage vaccine company, today announced that data from clinical and preclinical vaccine studies, including DPX-Survivac, the company’s lead therapeutic cancer vaccine, will be presented at the American Association for Cancer Research (AACR) 2014 Annual Meeting. The AACR Annual Meeting will be held April 5 – 9, 2014 in San Diego, California.
The first poster presentation will focus on study findings that support the belief that cancer treatment regimens that combine a vaccine with immune modulating agents such as metronomic cyclophosphamide, anti-PD-1 and anti-CTLA-4 may deliver enhanced therapeutic benefits. Details of the poster presentation are as follows:
Abstract #5028: Metronomic cyclophosphamide enhances the immunogenicity and anti-tumor activity of a DepoVax based vaccine and may be further enhanced with inhibitors of CTLA-4 or PD-1
Genevieve Weir, Research Scientist at Immunovaccine
Poster Board #20
Sunday, April 6, 2014, 1:00 – 5:00 p.m.
Location: Hall A-E Poster Section 27
A second poster related to DPX-Survivac in combination with metronomic low dose cyclophosphamide will also be presented during the AACR conference by Immunovaccine collaborator, Caprion’s ImmuneCarta business unit. This presentation will detail immune response results from Immunovaccine’s Phase I study of DPX-Survivac in ovarian cancer patients. Details of the poster presentation are as follows:
Abstract #CT411: Immune profiling of patients vaccinated with the survivin targeted therapeutic vaccine DPX-Survivac demonstrates durable polyfunctional CD4+ and CD8+ T cells in ovarian cancer patients
Yoav Peretz, Ph.D., Principal Scientist at ImmuneCarta Services
Poster Board #11
Wednesday, April 9, 2014, 8:00 a.m. – 12:00 p.m.
Location: Hall A-E Poster Section 38
DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. Survivin has been recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in solid tumors and blood cancers including ovarian, breast, colon and lung cancers, among others. Survivin plays an essential role in antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to various anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in a high percentage of cancer patients.
The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell immune response against cells presenting survivin peptides on HLA class I molecules. This targeted therapy attempts to use the immune system to actively search for tumor cells expressing survivin and destroy them.
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvants to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.
Connect at www.imvaccine.com
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Dr. Marc Mansour, Chief Operating Officer, Immunovaccine Inc.
T: (902) 492-1819 E: firstname.lastname@example.org
Tim Brons, Vida Strategic Partners (media)
T: (415) 675-7402 E: email@example.com
back to release list